YOU ARE HERE > MONEYCONTROL > MARKETS > PHARMACEUTICALS > News - Sun Pharmaceutical Industries

Sun Pharmaceutical Industries

BSE: 524715|NSE: SUNPHARMA|ISIN: INE044A01036|SECTOR: Pharmaceuticals
SET ALERT
|
ADD TO PORTFOLIO
|
WATCHLIST
LIVE
BSE
Jul 01, 16:01
826.70
-4.1 (-0.49%)
VOLUME 163,273
LIVE
NSE
Jul 01, 15:59
829.25
-1.35 (-0.16%)
VOLUME 2,316,527
News on Sun Pharmaceutical Industries
Select Year: 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2000-2005
Sun Pharma share price under pressure after surprise Q4 loss but CLSA expects 22% upside. Here's why

10.21 am | 31 May 2022 |  Source: Moneycontrol.com

The company posted a net loss of Rs 2,227.38 crore for the quarter under review, compared to the net profit of Rs 848 crore a year ago. Revenue for th...

Sun Pharma Q4 Result | Firm posts surprise loss of Rs 2,227 crore

3.41 pm | 30 May 2022 |  Source: Moneycontrol.com

The company also informed the stock exchanges that it has reappointed Dilip Shanghvi as its managing director for a five-year period....

Buy Sun Pharmaceutical Industries; target of Rs 1074: KR Choksey

9.56 pm | 03 Feb 2022 |  Source: Moneycontrol.com

KR Choksey is bullish on Sun Pharmaceutical Industries has recommended buy rating on the stock with a target price of Rs 1074 in its research report d...

Buy Sun Pharmaceutical Industries; target of Rs 1075: ICICI Direct

5.34 pm | 03 Feb 2022 |  Source: Moneycontrol.com

ICICI Direct is bullish on Sun Pharmaceutical Industries has recommended buy rating on the stock with a target price of Rs 1075 in its research report...

Buy Sun Pharmaceutical Industries; target of Rs 1075: ICICI Direct

5.34 pm | 03 Feb 2022 |  Source: Moneycontrol.com

ICICI Direct is bullish on Sun Pharmaceutical Industries has recommended buy rating on the stock with a target price of Rs 1075 in its research report...

Buy Sun Pharmaceutical Industries; target of Rs 1050: Prabhudas Lilladher

9.20 pm | 02 Feb 2022 |  Source: Moneycontrol.com

Prabhudas Lilladher is bullish on Sun Pharmaceutical Industries has recommended buy rating on the stock with a target price of Rs 1050 in its research...

Buy Sun Pharmaceutical Industries: target of Rs 1000: Sharekhan

5.59 pm | 01 Feb 2022 |  Source: Moneycontrol.com

Sharekhan is bullish on Sun Pharmaceutical Industries has recommended buy rating on the stock with a target price of Rs 1000 in its research report da...

Sun Pharma Consolidated December 2021 Net Sales at Rs 9,863.06 crore, up 11.61% Y-o-Y

10.11 am | 01 Feb 2022 |  Source: Moneycontrol.com

NULL...

Sun Pharma: Traction in specialty impressive

9.46 am | 01 Feb 2022 |  Source: Moneycontrol.com

Overall, traction for specialty products for Sun Pharma got a helping hand from the leading products Ilumya, Cequa, Levulan and Absorica...

Sun Pharma Consolidated December 2021 Net Sales at Rs 9,863.06 crore, up 11.61% Y-o-Y

11.23 pm | 31 Jan 2022 |  Source: Moneycontrol.com

NULL...

Sun Pharma Standalone December 2021 Net Sales at Rs 3,770.66 crore, up 11.29% Y-o-Y

11.11 pm | 31 Jan 2022 |  Source: Moneycontrol.com

NULL...

Sun Pharma Q3 Preview: Consolidated PAT to gain 10% YoY while revenue to rise 11%

8.19 pm | 30 Jan 2022 |  Source: Moneycontrol.com

Net sales for the quarter likely to rise 11.5 percent year-on-year growth to Rs 9853 crore for the December quarter...

Hold Sun Pharma; target of Rs 775: Emkay Global Financial

4.19 pm | 11 Jan 2022 |  Source: Moneycontrol.com

Emkay Global Financial recommended hold rating on Sun Pharma with a target price of Rs 775 in its research report dated January 10, 2022....

1 2
Quick Links for Sun Pharmaceutical Industries
Explore Moneycontrol
Stocks     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | Others
Mutual Funds     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.